 Tumor Necrosis Factor-alpha
"Tumor Necrosis Factor-alpha" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS.
| Descriptor ID |
D014409
|
| MeSH Number(s) |
D12.644.276.374.500.800 D12.644.276.374.750.626 D12.644.276.972.626 D12.776.124.900 D12.776.395.930 D12.776.467.374.500.800 D12.776.467.374.750.626 D12.776.467.972.626 D23.529.374.500.800 D23.529.374.750.626 D23.529.972.626
|
| Concept/Terms |
Tumor Necrosis Factor-alpha- Tumor Necrosis Factor-alpha
- Tumor Necrosis Factor alpha
- Cachectin-Tumor Necrosis Factor
- Cachectin Tumor Necrosis Factor
- TNFalpha
- TNF-alpha
- Tumor Necrosis Factor
- Tumor Necrosis Factor Ligand Superfamily Member 2
- Cachectin
- TNF Superfamily, Member 2
|
Below are MeSH descriptors whose meaning is more general than "Tumor Necrosis Factor-alpha".
Below are MeSH descriptors whose meaning is more specific than "Tumor Necrosis Factor-alpha".
This graph shows the total number of publications written about "Tumor Necrosis Factor-alpha" by people in this website by year, and whether "Tumor Necrosis Factor-alpha" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1987 | 1 | 0 | 1 | | 1988 | 4 | 0 | 4 | | 1989 | 4 | 3 | 7 | | 1990 | 7 | 3 | 10 | | 1991 | 10 | 2 | 12 | | 1992 | 6 | 5 | 11 | | 1993 | 2 | 3 | 5 | | 1994 | 6 | 4 | 10 | | 1995 | 11 | 7 | 18 | | 1996 | 6 | 3 | 9 | | 1997 | 4 | 5 | 9 | | 1998 | 2 | 7 | 9 | | 1999 | 4 | 12 | 16 | | 2000 | 4 | 6 | 10 | | 2001 | 10 | 10 | 20 | | 2002 | 13 | 10 | 23 | | 2003 | 11 | 12 | 23 | | 2004 | 17 | 16 | 33 | | 2005 | 8 | 10 | 18 | | 2006 | 10 | 15 | 25 | | 2007 | 15 | 15 | 30 | | 2008 | 6 | 13 | 19 | | 2009 | 10 | 8 | 18 | | 2010 | 7 | 13 | 20 | | 2011 | 8 | 15 | 23 | | 2012 | 10 | 17 | 27 | | 2013 | 11 | 6 | 17 | | 2014 | 4 | 11 | 15 | | 2015 | 5 | 12 | 17 | | 2016 | 2 | 9 | 11 | | 2017 | 7 | 9 | 16 | | 2018 | 4 | 9 | 13 | | 2019 | 5 | 8 | 13 | | 2020 | 1 | 5 | 6 | | 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Tumor Necrosis Factor-alpha" by people in Profiles.
-
Reid PD, Cifu AS, Bass AR. Management of Immunotherapy-Related Toxicities in Patients Treated With Immune Checkpoint Inhibitor Therapy. JAMA. 2021 Feb 02; 325(5):482-483.
-
Chakraborty S, Gonzalez J, Edwards K, Mallajosyula V, Buzzanco AS, Sherwood R, Buffone C, Kathale N, Providenza S, Xie MM, Andrews JR, Blish CA, Singh U, Dugan H, Wilson PC, Pham TD, Boyd SD, Nadeau KC, Pinsky BA, Zhang S, Memoli MJ, Taubenberger JK, Morales T, Schapiro JM, Tan GS, Jagannathan P, Wang TT. Proinflammatory IgG Fc structures in patients with severe COVID-19. Nat Immunol. 2021 01; 22(1):67-73.
-
Akiyama S, Yamada A, Sakuraba A. Safety of nontumor necrosis factor-targeted biologics in the COVID-19 pandemic. J Med Virol. 2021 02; 93(2):714-716.
-
Glick LR, Cifu AS, Feld L. Ulcerative Colitis in Adults. JAMA. 2020 Sep 22; 324(12):1205-1206.
-
Hou Q, Dong Y, Yu Q, Wang B, Le S, Guo Y, Zhang B. Regulation of the Paneth cell niche by exogenous L-arginine couples the intestinal stem cell function. FASEB J. 2020 08; 34(8):10299-10315.
-
Abasiyanik MF, Wolfe K, Van Phan H, Lin J, Laxman B, White SR, Verhoef PA, Mutlu GM, Patel B, Tay S. Ultrasensitive digital quantification of cytokines and bacteria predicts septic shock outcomes. Nat Commun. 2020 05 25; 11(1):2607.
-
Wang J, Prenner J, Wang W, Sakuraba A, Hyman N, Dalal S, Hurst R, Cohen RD, Umanskiy K, Shogan BD, Alpert L, Rubin DT, Colwell J, Pekow J. Risk factors and treatment outcomes of peristomal pyoderma gangrenosum in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2020 06; 51(12):1365-1372.
-
Katsumata K, Ishihara J, Fukunaga K, Ishihara A, Yuba E, Budina E, Hubbell JA. Conferring extracellular matrix affinity enhances local therapeutic efficacy of anti-TNF-a antibody in a murine model of rheumatoid arthritis. Arthritis Res Ther. 2019 12 23; 21(1):298.
-
Jain A, Irizarry-Caro RA, McDaniel MM, Chawla AS, Carroll KR, Overcast GR, Philip NH, Oberst A, Chervonsky AV, Katz JD, Pasare C. T cells instruct myeloid cells to produce inflammasome-independent IL-1ß and cause autoimmunity. Nat Immunol. 2020 01; 21(1):65-74.
-
Katsumata K, Ishihara J, Mansurov A, Ishihara A, Raczy MM, Yuba E, Hubbell JA. Targeting inflammatory sites through collagen affinity enhances the therapeutic efficacy of anti-inflammatory antibodies. Sci Adv. 2019 11; 5(11):eaay1971.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|